As the pandemic continues, shortages of rapid tests are expected. This firm is ramping up production on its less invasive way to test for Covid-19 that is currently waiting on regulatory approval.
Progressive medical device technology company Therma Bright Inc. (TSX Venture: THRM), in anticipation EUA approval to market its AcuVid™ Covid-19 Rapid Antigen Saliva Test has ordered sufficient materials and components to manufacture the first batch of AcuVid™ tests in the US.
The firm is also securing multiple manufacturing sites in different countries to be able to meet the anticipated demand for our test in the U.S. and elsewhere.
In a generally dismal day for markets, shares were trading down 1.27% in early afternoon trade.
